Xueshuantong Injection in Treating Deep Venous Thrombosis: A Systematic Review and Trial Sequential Analysis

Wenhui Li, Feng Xu, Renyan Huang, Weijing Fan, Changgeng Fu, Lei Xu, Xvhong Wang, Huimin Lü, Yuanxiang LiEvidence-based 2021 · DOI

TL;DR

This systematic review and trial sequential analysis (TSA) investigated the efficacy and safety of Xueshuantong injection, a traditional Chinese medicine, for treating Deep Venous Thrombosis (DVT). The findings suggest that Xueshuantong injection, when used as an add-on therapy, offers better clinical outcomes and fewer adverse events compared to conventional treatments, though this benefit should be viewed with caution due to study limitations.

What Problem Does This Paper Address?

Deep Venous Thrombosis (DVT) is a serious condition with a rising incidence, particularly in elderly inpatients. If left untreated, DVT can lead to chronic DVT syndrome or fatal pulmonary embolism. While conventional treatments exist, the paper explores the potential of Xueshuantong injection, a traditional Chinese medicine derived from Panax notoginseng, as a therapeutic option. The problem lies in the existing controversy and lack of comprehensive, systematic evaluation regarding the efficacy and safety of Xueshuantong injection for DVT. This study aims to bridge that gap by providing an evidence-based reference for clinical practice.

Methods

The researchers conducted a systematic review of randomized controlled trials (RCTs) published up to November 1, 2020, searching nine electronic databases for relevant literature. They employed a predefined search strategy using terms related to Xueshuantong and DVT. The primary outcomes assessed were the clinical effective rate and the incidence rate of adverse events. Secondary outcomes included various measures of venous patency (femoral, popliteal, posterior tibial veins), circumference differences in the limbs, activated partial thromboplastin time (APTT), and D-dimer (D-D) levels.

Meta-analysis was performed using RevMan 5.4.1 to analyze the collected data. To assess the robustness and reliability of the findings, Trial Sequential Analysis (TSA) was utilized. This method helps determine if the accumulated evidence is sufficient to reach a firm conclusion, considering the risk of both Type I and Type II errors.

Datasets

The study did not introduce new datasets. Instead, it systematically reviewed and analyzed data from 12 existing randomized controlled trials (RCTs) that met the inclusion criteria.

Key Insights and Ideas

  • Xueshuantong's Promising Add-on Role: The study strongly suggests that Xueshuantong injection, when used in conjunction with conventional DVT treatments, leads to superior clinical effectiveness. This implies it could be a valuable adjunct therapy.
  • Improved Venous Patency and Biomarkers: Beyond overall clinical effectiveness, Xueshuantong appears to positively impact key physiological markers. This includes improved patency rates of major leg veins and favorable changes in D-dimer and APTT levels, which are crucial indicators of clotting and blood flow.
  • Lower Adverse Event Incidence: A significant finding is that Xueshuantong injection was associated with a lower incidence of adverse events compared to conventional treatments, suggesting a potentially better safety profile.
  • Need for Caution Despite Positive Results: Despite the statistically significant positive findings, the authors emphasize caution. This is primarily due to the limited number of studies included and the identified high or unclear risk of bias in these studies.

Key Results

The meta-analysis included 12 RCTs with a total of 1018 patients. Key findings include:

  • Clinical Effective Rate: Xueshuantong injection showed a significantly higher clinical effective rate (OR = 4.68, 95% CI [2.79, 7.86], P < 0.00001) compared to conventional treatment, with no heterogeneity among studies.
  • Incidence Rate of Adverse Events: Xueshuantong injection was associated with a lower incidence of adverse events (OR = 0.48, 95% CI [0.27, 0.84], P = 0.01), with no heterogeneity.
  • Venous Patency: Significant improvements were observed in the patency rates of the femoral vein (OR = 1.45, P = 0.23), popliteal vein (OR = 1.59, P = 0.18), and posterior tibial vein (OR = 1.08, P = 0.33) in the Xueshuantong group, though the statistical significance for these secondary outcomes varied.
  • Circumference Difference: Significant improvements were noted in the circumference difference of both upper (OR = -1.25, P < 0.00001) and lower knee limbs (OR = -1.08, P < 0.00001).
  • APTT and D-Dimer: Xueshuantong injection significantly improved APTT (OR = 3.52, P = 0.00001) and D-D levels (OR = -2.42, P < 0.00001). Notably, APTT analysis revealed considerable heterogeneity initially, which was reduced after excluding two studies.
  • Trial Sequential Analysis (TSA): The TSA for clinical effectiveness indicated that the evidence was sufficient to reach a positive conclusion, crossing the traditional and TSA boundaries.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size and Study Quality: The meta-analysis was based on a relatively small number of studies, and many of these studies had a high or unclear risk of bias, particularly concerning allocation concealment and blinding.
  • Heterogeneity: While some outcomes showed no heterogeneity, others, like APTT, did, requiring careful interpretation.
  • Limited Database Search: The search was primarily focused on Chinese databases, with a lack of relevant studies found in English language databases, potentially introducing bias and limiting the global representation of the findings.
  • Incomplete Data: Some articles were excluded due to missing key data, which could have biased the results.

Future work should focus on conducting high-quality RCTs with standardized reporting, homogeneous outcome indicators, and reduced bias to further validate these findings and establish a stronger evidence base for Xueshuantong injection in DVT treatment.

Summary updated

Abstract

Based on the current analysis, Xueshuantong injection as an add-on treatment provided better treatment effect for DVT with adequate power but this benefit should be considered with caution because of the small number of studies included in the meta-analysis and the high or unclear risk of bias of the included trials, suggesting that further studies are needed.
BibTeX
@inproceedings{li2021xueshuantong,
  author = {Wenhui Li and Feng Xu and Renyan Huang and Weijing Fan and Changgeng Fu and Lei Xu and Xvhong Wang and Huimin Lü and Yuanxiang Li},
  title = {{Xueshuantong Injection in Treating Deep Venous Thrombosis: A Systematic Review and Trial Sequential Analysis}},
  booktitle = {Evidence-based},
  year = {2021},
  doi = {10.1155/2021/6622925},
}
Figure